ACHIEVE-J was a multicentre, randomised, open-label phase 3 study at 40 Japanese centres. 401 adults with type 2 diabetes, managed on diet and exercise alone or with one or two oral glucose-lowering drugs, were assigned in equal numbers to once-daily oral orforglipron at 3 mg, 12 mg or 36 mg. The primary endpoint was safety over 52 weeks, and 352 (88 per cent) completed treatment. There was no placebo arm and no masking, so this tells you about tolerability, not about how well the drug works compared with anything else.
339 participants (85 per cent, 95% CI 80.7 to 87.8) had at least one treatment-emergent adverse event, most of them mild (67 per cent) or moderate (16 per cent). Discontinuation for adverse events tracked the dose: 5 per cent (2.6 to 10.5) at 3 mg, 8 per cent (4.6 to 14.0) at 12 mg and 14 per cent (9.3 to 21.1) at 36 mg, with gastrointestinal symptoms the commonest reason at every dose. Level 2 hypoglycaemia, meaning blood glucose below 54 mg/dL, occurred in 2 per cent at both 12 mg and 36 mg, and there was no severe hypoglycaemia at all. Results were similar whatever the background therapy.
This dataset matters more in Indian practice than a US or European trial of the same drug would. Type 2 diabetes in East Asian populations is driven more by beta-cell secretory failure at lower body mass index, which sits closer to the Indian phenotype than the populations most GLP-1 trials recruit. An oral GLP-1 receptor agonist removes the injection, the pen and the cold chain, which are three of the practical reasons this class is under-used here. Nothing to prescribe yet, but this is the evidence stream to follow, and the dose-tolerability gradient is the part to remember when it arrives.
- Read this as safety data only - open-label, no placebo, no efficacy comparison.
- Expect roughly one in seven patients to stop the highest dose because of side effects.
- Gastrointestinal symptoms drive discontinuation here, just as they do with injectable GLP-1 receptor agonists.
- Hypoglycaemia was uncommon and never severe, even added on to existing oral agents.
- For patients asking whether the injection can be swapped for a tablet, this is the class - but it is not yet available in India.
The statistics, in plain English
The confidence intervals around the discontinuation rates are wide - 9.3 to 21.1 per cent at the top dose - because each group had only about 134 people, so the true rate could be nearer one in ten or nearer one in five. What you can trust is the direction: the rate climbed with every dose step. Because the study was open-label and had no placebo group, some of the 85 per cent adverse-event rate is simply what happens to any group of people with diabetes over a year, and there is no comparator to subtract that background from. That is why a safety trial like this tells you what to warn patients about but cannot tell you how much of it the drug caused.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free